MicroPort

MicroPort is a global medical device developer and manufacturer that is headquartered in Shanghai, China. It designs and produces products for a range of medical fields including cardiology, interventional radiology, orthopedics, electrophysiology, and surgical management.[2] MicroPort is considered to be among the top 100 medical device companies in 2018 and was selected to be the 2017 China Innovative Medical Device Company.[3][4]

MicroPort Inc.
TypePublic
SEHK: 853
IndustryMedical Devices
Founded1998
HeadquartersShanghai, China
Key people
Zhaohua Chang, CEO
Glendy Wang, COO
Martin Sun, CFO
Qiyi Luo, CTO
Revenue US$793.493Million (2019 Annual)[1]
US$564.425 Million (2019 Annual)[1]
US$29.009 Million (2019 Annual)[1]
Number of employees
5000 (2018)
Websitewww.microport.com

History

MicroPort was founded in 1998 by Zhaohua Chang, who currently serves as CEO, Chairman, and Director.[5] The company rose to prominence from the early success of its coronary stent line due its focus on serving the needs of the Chinese device market.[6][7] It is now one of the top global manufacturers of cardiac interventional devices.[8] Notably, it produces the world's first and only commercially available targeted drug eluting stent system, which uses a significantly reduced amount of drug than traditional drug eluting stents while maintaining effectiveness.[9][10][11][12] As of early 2018, MicroPort is one of few medical device companies still developing a commercial coronary bioresorbable stent with ongoing clinical trials.[13][14][15]

Beginning in the 2010s, MicroPort has rapidly expanded around the world via international acquisitions to other medical device industries, including orthopedics and cardiac rhythm management, and is valued at over US$1 Billion.[16][17]

In 2019, MicroPort announced a US$398 Million investment to develop pacemakers and defibrillators in France.[18]

Acquisitions

In 2014 MicroPort expanded operations in the United States by acquiring Wright Medical's OrthoRecon business to become the 6th largest international producer of orthopedic devices.[19] MicroPort's orthopedic business is based in Arlington, Tennessee and in 2018 has expanded its business into India.[20]

In 2018 MicroPort and LivaNova closed the sale of LivaNova's cardiac rhythm management business for $190M.[17]

In 2018 MicroPort purchased Lombard Medical, a US-based endovascular device company, from bankruptcy after it defaulted on loans in early 2018.[21]

References
  1. "MicroPort Annual Report 2019" (PDF). MicroPort.
  2. "About Us". MicroPort. MicroPort.
  3. Top 100 Medical Device Companies, Greenlight Guru
  4. "MicroPort Scientific : Æ Selected as "2017 China Innovative Medical Device Co". MarketScreener.
  5. "Zhaohua Chang Ph.D". MicroPort.
  6. "Company Overview of Shanghai MicroPort Medical (Group) Co., Ltd". Bloomberg.
  7. "Solution seeker: medical device developer provides international standards at lower price for Chinese patients". South China Morning Post.
  8. "Global Cardiac Catheters Market Share 2018 Microport, Terumo, Cook and Lepu". Publicist Report.
  9. Lansky, Alexandra; Wijns, William; Xu, Bo; KelbÊk, Henning; van Royen, Niels; Zheng, Ming; Morel, Marie-angËle; Knaapen, Paul; Slagboom, Ton; Johnson, Thomas W; Vlachojannis, Georgios; Arkenbout, Karin E; Holmvang, Lene; Janssens, Luc; Ochala, Andrez; Brugaletta, Salvatore; Naber, Christoph K; Anderson, Richard; Rittger, Harald; Berti, Sergio; Barbato, Emanuele; Toth, Gabor G; Maillard, Luc; Valina, Christian; Buszman, Pawel; Thiele, Holger; Sch‰chinger, Volker; Baumbach, Andreas (September 29, 2018). "Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial". The Lancet. 392 (10153): 1117–1126. doi:10.1016/S0140-6736(18)31649-0. PMID 30190206.
  10. Gao, RL (20 May 2013). "A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial". Eurointervention. 9 (1): 75–83. doi:10.4244/EIJV9I1A12. PMID 23685298.
  11. Xu, B; Gao, RL; Zhang, RY; Wang, HC; Li, ZQ; Yang, YJ; Ma, CS; Han, YL; Lansky, AJ; Huo, Y; Li, W; Leon, MB (March 2013). "Efficacy and safety of FIREHAWKÆ abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort". China Medical Journal. 126 (6): 1026–32. PMID 23506573.
  12. "Round Table Expert - Firehawk Stent, proven fast healing from TARGET clinical program". EuroPCR.
  13. Regazzoli, Damiano; Leone, Pier Pasquale; Colombo, Antonio; Latib, Azeem (9 August 2017). "New generation bioresorbable scaffold technologies: an update on novel devices and clinical results". Journal of Thoracic Disease. 9 (Suppl 9): S979–S985. doi:10.21037/jtd.2017.07.104. PMC 5583081. PMID 28894604.
  14. Wendling, Patrice. "Boston Scientific Halts Bioabsorbable-Scaffold Program". Medscape. WebMD.
  15. Fornell, Dave. "Abbott Will End Sales of Absorb Bioresorbable Stent". Diagnostic and Interventional Cardiology. Scranton Gillette Communications.
  16. "Surprising MicroPort Orthopedics". Orthopedics This Week.
  17. "LivaNova closes $190 CRM sale to MicroPort". Mass Device.
  18. "French leader promotes foreign investment at Versailles". Washington Post.
  19. "MicroPort Scientific establishes MicroPort Orthopedics through acquisition of Wright Medical's OrthoRecon business". Cision PR Newswire.
  20. "MicroPort forays into orthopaedic implants". The Hans India.
  21. "Lombard Medical Operations Acquired by MicroPort Scientific Corporation in a Restructuring Transaction". PR Newswire Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.